 Alan Elder
Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Semaphorins | 4 | 2025 | 37 | 1.780 |
Why?
| | Antigens, CD | 5 | 2025 | 558 | 1.490 |
Why?
| | Mammary Glands, Animal | 3 | 2025 | 128 | 1.130 |
Why?
| | Breast Neoplasms | 6 | 2025 | 2393 | 1.010 |
Why?
| | Prions | 2 | 2015 | 59 | 0.820 |
Why?
| | B7-H1 Antigen | 2 | 2025 | 244 | 0.780 |
Why?
| | Lymphatic Vessels | 3 | 2020 | 63 | 0.770 |
Why?
| | Immune Tolerance | 1 | 2025 | 385 | 0.740 |
Why?
| | Macrophages | 2 | 2020 | 1507 | 0.680 |
Why?
| | Postpartum Period | 3 | 2020 | 373 | 0.650 |
Why?
| | Breast | 1 | 2020 | 156 | 0.590 |
Why?
| | Mammary Glands, Human | 1 | 2018 | 68 | 0.540 |
Why?
| | Epithelial Cells | 2 | 2021 | 1134 | 0.460 |
Why?
| | Extracellular Matrix | 1 | 2020 | 562 | 0.460 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1450 | 0.410 |
Why?
| | Prion Diseases | 1 | 2013 | 21 | 0.400 |
Why?
| | Neoplasm Metastasis | 3 | 2025 | 688 | 0.290 |
Why?
| | Tumor Microenvironment | 3 | 2025 | 735 | 0.290 |
Why?
| | Aurora Kinase A | 1 | 2026 | 61 | 0.240 |
Why?
| | Cell Line, Tumor | 5 | 2026 | 3551 | 0.240 |
Why?
| | GPI-Linked Proteins | 3 | 2025 | 81 | 0.230 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2026 | 66 | 0.230 |
Why?
| | Azepines | 1 | 2026 | 105 | 0.230 |
Why?
| | Cell Plasticity | 1 | 2025 | 37 | 0.220 |
Why?
| | Mesocricetus | 2 | 2015 | 52 | 0.210 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2025 | 177 | 0.210 |
Why?
| | Pyrimidines | 1 | 2026 | 530 | 0.180 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 2 | 2019 | 66 | 0.170 |
Why?
| | Anoikis | 1 | 2021 | 31 | 0.170 |
Why?
| | Mice | 6 | 2026 | 18355 | 0.160 |
Why?
| | Animals | 8 | 2026 | 38097 | 0.160 |
Why?
| | Protein Kinase Inhibitors | 1 | 2026 | 981 | 0.150 |
Why?
| | Membrane Glycoproteins | 2 | 2019 | 499 | 0.140 |
Why?
| | Mice, Inbred BALB C | 2 | 2019 | 1261 | 0.140 |
Why?
| | Lactation | 1 | 2020 | 193 | 0.140 |
Why?
| | Lymphangiogenesis | 1 | 2018 | 27 | 0.140 |
Why?
| | Crosses, Genetic | 1 | 2018 | 123 | 0.140 |
Why?
| | Integrins | 1 | 2018 | 90 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1505 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2019 | 266 | 0.130 |
Why?
| | Mice, Knockout | 2 | 2025 | 3130 | 0.120 |
Why?
| | Administration, Intranasal | 1 | 2015 | 94 | 0.110 |
Why?
| | Deer | 1 | 2015 | 43 | 0.110 |
Why?
| | Injections, Intravenous | 1 | 2015 | 197 | 0.110 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 109 | 0.110 |
Why?
| | Aging | 1 | 2025 | 1973 | 0.100 |
Why?
| | Phosphotungstic Acid | 1 | 2013 | 1 | 0.100 |
Why?
| | Cell Movement | 1 | 2018 | 961 | 0.100 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5992 | 0.100 |
Why?
| | Female | 7 | 2026 | 79035 | 0.100 |
Why?
| | Cricetinae | 1 | 2013 | 305 | 0.100 |
Why?
| | Administration, Oral | 1 | 2015 | 867 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2018 | 877 | 0.090 |
Why?
| | Humans | 8 | 2026 | 145763 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1723 | 0.070 |
Why?
| | Molecular Docking Simulation | 1 | 2026 | 119 | 0.060 |
Why?
| | Time Factors | 1 | 2015 | 7133 | 0.050 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2025 | 220 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2026 | 936 | 0.050 |
Why?
| | Integrin alpha6 | 1 | 2021 | 9 | 0.040 |
Why?
| | Caspase 7 | 1 | 2021 | 22 | 0.040 |
Why?
| | Integrin beta1 | 1 | 2021 | 33 | 0.040 |
Why?
| | Caspase 3 | 1 | 2021 | 242 | 0.040 |
Why?
| | Enzyme Activation | 1 | 2021 | 762 | 0.040 |
Why?
| | Adipocytes | 1 | 2021 | 223 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2021 | 770 | 0.040 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2021 | 337 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2021 | 440 | 0.040 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2019 | 62 | 0.040 |
Why?
| | Cell Proliferation | 1 | 2026 | 2514 | 0.040 |
Why?
| | Cell Survival | 1 | 2021 | 1103 | 0.030 |
Why?
| | Phosphorylation | 1 | 2021 | 1708 | 0.030 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2021 | 883 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 3170 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2019 | 923 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2019 | 1146 | 0.020 |
Why?
| | Male | 1 | 2015 | 73003 | 0.020 |
Why?
| | Adult | 1 | 2025 | 40872 | 0.010 |
Why?
|
|
Elder's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|